Concepedia

Roger G. Hall

RG

21

Publications

1.6K

Citations

17

H-Index

1982

Active since

Affiliations

Novartis (Switzerland)(Current)

Central Research Laboratories (United Kingdom)

Syngenta (Switzerland)

The University of Sydney

Syngenta (United Kingdom)

Roger G. Hall is an author at Novartis (Switzerland) specializing in pharmacology, medicine, and organic chemistry.

Top concepts

PharmacologyMedicineOrganic ChemistryChemistryNatural SciencesBiochemistryNeuropharmacologyMolecular PharmacologyDrug DiscoveryEngineering

Publications per year

1982–2015

21

Publications

21

CGP 35348: a centrally active blocker of GABAB receptors

Hans-Rudolf Olpe, Göril Karlsson, Mario F. Pozza et al. · European Journal of Pharmacology · 1990 · 309 citations

Molecular Pharmacology, G Protein-coupled Receptor, Medicine +5

The Importance of Fluorine in the Life Science Industry

Peter Maienfisch, Roger G. Hall · CHIMIA International Journal for Chemistry · 2004 · 218 citations · Full text

Pharmaceutical Science, Engineering, Organic Chemistry +17

Phosphinic Acid Analogs of GABA. 2. Selective, Orally Active GABAB Antagonists

Wolfgang Froestl, Stuart J. Mickel, G. VON SPRECHER et al. · Journal of Medicinal Chemistry · 1995 · 206 citations · Full text

Phosphinic Acid Analogs of GABA. 1. New Potent and Selective GABAB Agonists

Wolfgang Froestl, Stuart J. Mickel, Roger G. Hall et al. · Journal of Medicinal Chemistry · 1995 · 202 citations · Full text

Novel Gabab Antagonists, Pharmacotherapy, Pharmaceutical Chemistry +16

Investigating the mode of action of sulfoxaflor: a fourth‐generation neonicotinoid

Penny Cutler, Russell Slater, Andrew Edmunds et al. · Pest Management Science · 2012 · 123 citations

Rows per page

1–5 of 21